Trial Profile
Safety of nivolumab and ipilimumab in patients with multiple advanced cancers.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jun 2016
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma
- Focus Adverse reactions
- 21 Jun 2016 New trial record
- 15 Jun 2016 Results published in the Annals of the Rheumatic Diseases